Loading...

Vascular Cures Research Network

1,124 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Jun 17, 2011

Vascular Cures Research Network

The initial focus of the Vascular Cures Research Network (VCRN) will be peripheral artery disease (PAD), which is usually caused by atherosclerosis, a build-up of plaque in the arteries of the leg. PAD can cause significant pain and inability to walk as well as potential amputation. PAD affects 10 million Americans, requiring hundreds of thousands of surgeries and causing over 80,000 amputations.

Surgical bypass and angioplasty/stenting are the primary PAD treatments to restore blocked blood flow. While initially successful, there is often subsequent re-narrowing of the artery or graft resulting from abnormal scar formation known as restenosis. The failure rates of angioplasty are as high as 50% within 1 -- 2 years, whereas vein bypass has a failure rate of 30 -- 50% over 5 years. This results in the need for multiple interventions with additional complications, risks, and costs.

Vascular Cures is launching a unique project focused on the problem of PAD treatment failures due to restenosis. Our overall goal is to develop treatments and technologies to significantly reduce the failure rate of peripheral vascular repairs within 5 years. This ground-breaking translational program provides the best chance to develop new treatments, by being the first to identify the biological and genetic contributors to PAD restenosis. We will collect and analyze samples from over 2000 patients -- an achievement that has never been possible before.

As part of this project, Vascular Cures will create the first national vascular consortium (VCRN) of vascular surgeons at up to 15 medical institutions around the US who will collaborate in translational projects targeting common vascular diseases such as PAD. While restenosis is the first project, the consortium will continue to work together over a number of years -- a powerful resource for medical research and industry that will accelerate the development of new technologies. The project will generate another transformational and permanent research asset -- a biobank of tissues from 2000 patients and a database of results from analyzing the genetic and proteomic characteristics of these tissues, and their correlation with clinical outcomes. There has never been a national effort on this scale to address this great unmet scientific need in the care of the PAD patient.

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...